Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Wintermute founder: The crash was caused by multiple factors, with excessive market leverage being a key issue

Wintermute founder: The crash was caused by multiple factors, with excessive market leverage being a key issue

ChaincatcherChaincatcher2025/10/20 03:17
Show original

ChainCatcher news, Wintermute founder Evgeny Gaevoy stated in The Block's podcast that, "I believe the crash was the result of multiple factors combined. On one hand, there is indeed more leverage in the system; on the other hand, the market now has more types of tokens, more perpetual contract products, and more large platforms trading these perpetual contracts. Looking back three or four years ago, we simply didn't have so many perpetual contract products with huge open interest and enormous crash risks. In terms of market maturity, although the overall system is indeed more complete and sophisticated than before, this development has also brought about many problems. It is still unclear who exactly was 'liquidated' and who suffered the most losses, but I suspect that many institutions with heavy losses were actually running long-short hedging strategies. For example, they might have shorted bitcoin and gone long on some altcoins, thinking this would hedge their risks, but in the end, they were 'slapped in the face' by the ADL mechanism."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11